Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved LITAK til behandling af hårcelleleukæmi opvejer risiciene.
The Committee for Medicinal Products for Human Use (CHMP) decided that LITAK’ s benefits are greater than its risks for the treatment of hairy cell leukaemia.